Sequent Scientific jumped 4.24% to Rs 150.05 after the company said it entered into definitive agreement with Dr. Huseyin Aydin for the acquisition of 40% stake from him in Provet for $17.10 million.
Sequent will acquire the stake through its Ireland-based wholly-owned subsidiary, Alivira Animal Health. The transaction is expected to be completed on or before 31 October 2020.Alivira Animal Health currently holds 60% stake in Provet which it acquired in 2014. Provet is among the top three and the largest local company in veterinary medicines market in Turkey having market share of 10%. Sequent said the object of acquisition is to consolidate the shareholding in Provet. Consequent to this acquisition, Provet will become a wholly owned subsidiary of the company.
Provet has manufacturing facilities located at Polatli Industrial Zone, Ankara, Turkey. The Ankara facility is EUGMP and Turkish GMP approved with 8 different manufacturing lines. Provet operates in various dosage forms mainly dominated by injectables (solutions/suspensions), oral solutions, pour-on/spot-on, aerosols and intrauterine. There are more than 120 product registrations.
On a consolidated basis, Sequent Scientific posted a 60% surge in net profit to Rs 24.47 crore on a 11.6% rise in net sales to Rs 310.27 crore in Q1 June 2020 over Q1 June 2019.
Sequent is the largest Indian pure-play animal healthcare company with global operations. SeQuent provides animal health Active Pharmaceutical Ingredients (API), formulations, and analytical services in over 100 countries, with more than 1,700 employees and manufacturing operations in India, Spain, Turkey, Germany and Brazil.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU